- Home
- WRLD vs KRRO Comparison
WRLD vs KRRO Comparison
Compare WRLD & KRRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WRLD
- KRRO
- Stock Information
- Founded
- WRLD 1962
- KRRO 2014
- Country
- WRLD United States
- KRRO United States
- Employees
- WRLD N/A
- KRRO N/A
- Industry
- WRLD Finance: Consumer Services
- KRRO Biotechnology: Pharmaceutical Preparations
- Sector
- WRLD Finance
- KRRO Health Care
- Exchange
- WRLD Nasdaq
- KRRO Nasdaq
- Market Cap
- WRLD 690.7M
- KRRO 630.4M
- IPO Year
- WRLD 1991
- KRRO 2019
- Fundamental
- Price
- WRLD $122.39
- KRRO $69.10
- Analyst Decision
- WRLD
- KRRO Strong Buy
- Analyst Count
- WRLD 0
- KRRO 6
- Target Price
- WRLD N/A
- KRRO $134.60
- AVG Volume (30 Days)
- WRLD 19.2K
- KRRO 203.2K
- Earning Date
- WRLD 10-25-2024
- KRRO 11-27-2024
- Dividend Yield
- WRLD N/A
- KRRO N/A
- EPS Growth
- WRLD 57.36
- KRRO N/A
- EPS
- WRLD 14.74
- KRRO N/A
- Revenue
- WRLD $557,738,702.00
- KRRO N/A
- Revenue This Year
- WRLD N/A
- KRRO N/A
- Revenue Next Year
- WRLD $0.78
- KRRO N/A
- P/E Ratio
- WRLD $8.58
- KRRO N/A
- Revenue Growth
- WRLD N/A
- KRRO N/A
- 52 Week Low
- WRLD $100.92
- KRRO $30.01
- 52 Week High
- WRLD $149.31
- KRRO $98.00
- Technical
- Relative Strength Index (RSI)
- WRLD 58.71
- KRRO 65.24
- Support Level
- WRLD $111.97
- KRRO $59.20
- Resistance Level
- WRLD $128.21
- KRRO $72.15
- Average True Range (ATR)
- WRLD 3.31
- KRRO 7.18
- MACD
- WRLD 0.67
- KRRO -0.57
- Stochastic Oscillator
- WRLD 64.16
- KRRO 46.82
About WRLD World Acceptance Corporation
World Acceptance Corp operates a small-loan consumer finance business. The company offers short-term small installment loans, medium-term larger installment loans, related credit insurance and ancillary products and services to individuals. It also offers income tax return preparation services to its loan customers and other individuals.
About KRRO Korro Bio Inc.
Korro Bio Inc is a biopharmaceutical company with a mission to discover, develop, and commercialize a new class of genetic medicines based on editing RNA, enabling the treatment of both rare and highly prevalent diseases. It is generating a portfolio of differentiated programs that are designed to harness the body's natural RNA editing process to effect a precise yet transient single base edit. By editing RNA instead of DNA, Korro Bio is expanding the reach of genetic medicines by delivering additional precision and tunability.